Mersana Therapeutics and Merck KGaA announced an biotech partnering to collaboratively develop next-generation antibody-drug conjugates (ADCs) for $792 million.
ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumor site.
Mersana and the biopharmaceutical division of Merck KGaA will leverage Mersana’s Fleximer technology to generate ADCs for multiple undisclosed targets.
Both parties have agreed to test a variety of ADCs by utilizing Mersana’s platform technologies and several cytotoxic agents as conjugates.
Merck KGaA will provide monoclonal antibodies to Mersana, which will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities.
Merck KGaA will be responsible for clinical development and commercialization of any products under an exclusive license from Mersana.
In addition to an upfront payment, Mersana is eligible to receive milestones plus royalties on worldwide net sales of products.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Merck & Co
Report: Partnering Deals and Alliances with Merck KgaA / Merck Serono
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity